You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMephentermine
Accession NumberDB01365
TypeSmall Molecule
GroupsApproved
DescriptionA sympathomimetic agent with mainly indirect effects on adrenergic receptors. It is used to maintain blood pressure in hypotensive states, for example, following spinal anesthesia. Although the central stimulant effects of mephentermine are much less than those of amphetamine, its use may lead to amphetamine-type dependence. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1248)
Structure
Thumb
Synonyms
Mephentermine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Wyamine Sulfate Injection Liq 30mg/mlliquid30 mgintramuscular; intravenousWyeth Ayerst Canada Inc.1994-12-311998-12-15Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
WyamineNot Available
WyfenterminaNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Mephentermine sulfate
ThumbNot applicableDBSALT001074
Categories
UNIITEZ91L71V4
CAS number100-92-5
WeightAverage: 163.2594
Monoisotopic: 163.136099549
Chemical FormulaC11H17N
InChI KeyInChIKey=RXQCGGRTAILOIN-UHFFFAOYSA-N
InChI
InChI=1S/C11H17N/c1-11(2,12-3)9-10-7-5-4-6-8-10/h4-8,12H,9H2,1-3H3
IUPAC Name
methyl(2-methyl-1-phenylpropan-2-yl)amine
SMILES
CNC(C)(C)CC1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenethylamines
Direct ParentAmphetamines and derivatives
Alternative Parents
Substituents
  • Amphetamine or derivatives
  • Phenylpropane
  • Aralkylamine
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationUsed to maintain blood pressure in hypotensive states.
PharmacodynamicsMephentermine is a sympathomimetic agent with mainly indirect effects on adrenergic receptors. It is used to maintain blood pressure in hypotensive states, for example, following spinal anesthesia. Although the central stimulant effects of mephentermine are much less than those of amphetamine, its use may lead to amphetamine-type dependence. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1248)
Mechanism of actionMephentermine is an alpha adrenergic receptor agonist, but also acts indirectly by releasing endogenous norepinephrine. Cardiac output and systolic and diastolic pressures are usually increased. A change in heart rate is variable, depending on the degree of vagal tone. Sometimes the net vascular effect may be vasodilation. Large doses may depress the myocardium or produce central nervous system (CNS) effects.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic, by N-demethylation and then p-hydroxylation.

Route of eliminationNot Available
Half life17 to 18 hours.
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9925
Blood Brain Barrier+0.9664
Caco-2 permeable+0.7962
P-glycoprotein substrateNon-substrate0.5711
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.9574
Renal organic cation transporterNon-inhibitor0.775
CYP450 2C9 substrateNon-substrate0.7797
CYP450 2D6 substrateSubstrate0.7109
CYP450 3A4 substrateNon-substrate0.5507
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.923
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8388
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8682
Ames testNon AMES toxic0.979
CarcinogenicityNon-carcinogens0.8079
BiodegradationNot ready biodegradable0.9633
Rat acute toxicity2.8952 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9804
hERG inhibition (predictor II)Non-inhibitor0.872
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Liquidintramuscular; intravenous30 mg
PricesNot Available
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point< 25 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.457 mg/mLALOGPS
logP2.54ALOGPS
logP2.52ChemAxon
logS-2.5ALOGPS
pKa (Strongest Basic)10.3ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area12.03 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity53.12 m3·mol-1ChemAxon
Polarizability19.79 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.87 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesC01CA11
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypertensive activities of Mephentermine.
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Mephentermine.
AcepromazineAcepromazine may decrease the stimulatory activities of Mephentermine.
AceprometazineAceprometazine may decrease the stimulatory activities of Mephentermine.
AcetazolamideAcetazolamide may decrease the excretion rate of Mephentermine which could result in a lower serum level and potentially a reduction in efficacy.
AcetophenazineAcetophenazine may decrease the stimulatory activities of Mephentermine.
AcrivastineMephentermine may decrease the sedative activities of Acrivastine.
AlcaftadineMephentermine may decrease the sedative activities of Alcaftadine.
AlfentanilMephentermine may increase the analgesic activities of Alfentanil.
AlfuzosinAlfuzosin may decrease the vasoconstricting activities of Mephentermine.
AlimemazineMephentermine may decrease the sedative activities of Alimemazine.
AlphacetylmethadolMephentermine may increase the analgesic activities of Alphacetylmethadol.
Aluminum hydroxideAluminum hydroxide may decrease the excretion rate of Mephentermine which could result in a lower serum level and potentially a reduction in efficacy.
Aluminum phosphateAluminum phosphate may decrease the excretion rate of Mephentermine which could result in a lower serum level and potentially a reduction in efficacy.
AmineptineAmineptine may increase the stimulatory activities of Mephentermine.
AmisulprideAmisulpride may decrease the stimulatory activities of Mephentermine.
AmitriptylineAmitriptyline may increase the stimulatory activities of Mephentermine.
Ammonium chlorideThe serum concentration of Mephentermine can be decreased when it is combined with Ammonium chloride.
AmperozideAmperozide may decrease the stimulatory activities of Mephentermine.
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Mephentermine.
AntazolineMephentermine may decrease the sedative activities of Antazoline.
AripiprazoleAripiprazole may decrease the stimulatory activities of Mephentermine.
AsenapineAsenapine may decrease the stimulatory activities of Mephentermine.
AstemizoleMephentermine may decrease the sedative activities of Astemizole.
AtomoxetineAtomoxetine may increase the hypertensive activities of Mephentermine.
AzaperoneAzaperone may decrease the stimulatory activities of Mephentermine.
AzatadineMephentermine may decrease the sedative activities of Azatadine.
AzelastineMephentermine may decrease the sedative activities of Azelastine.
BenmoxinBenmoxin may increase the hypertensive activities of Mephentermine.
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Mephentermine.
Benzylpenicilloyl PolylysineMephentermine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.
BezitramideMephentermine may increase the analgesic activities of Bezitramide.
BifeprunoxBifeprunox may decrease the stimulatory activities of Mephentermine.
Bismuth SubcitrateBismuth Subcitrate may decrease the excretion rate of Mephentermine which could result in a lower serum level and potentially a reduction in efficacy.
BrexpiprazoleBrexpiprazole may decrease the stimulatory activities of Mephentermine.
BromocriptineBromocriptine may increase the hypertensive activities of Mephentermine.
BrompheniramineMephentermine may decrease the sedative activities of Brompheniramine.
BuclizineMephentermine may decrease the sedative activities of Buclizine.
BuprenorphineMephentermine may increase the analgesic activities of Buprenorphine.
Butanoic AcidMephentermine may decrease the sedative activities of Butanoic Acid.
ButorphanolMephentermine may increase the analgesic activities of Butorphanol.
CabergolineCabergoline may increase the hypertensive activities of Mephentermine.
Calcium carbonateCalcium carbonate may decrease the excretion rate of Mephentermine which could result in a lower serum level and potentially a reduction in efficacy.
CarbinoxamineMephentermine may decrease the sedative activities of Carbinoxamine.
CarfentanilMephentermine may increase the analgesic activities of Carfentanil.
CariprazineCariprazine may decrease the stimulatory activities of Mephentermine.
CaroxazoneCaroxazone may increase the hypertensive activities of Mephentermine.
CarvedilolCarvedilol may decrease the vasoconstricting activities of Mephentermine.
CeliprololThe risk or severity of adverse effects can be increased when Mephentermine is combined with Celiprolol.
CetirizineMephentermine may decrease the sedative activities of Cetirizine.
ChloropyramineMephentermine may decrease the sedative activities of Chloropyramine.
ChlorphenamineMephentermine may decrease the sedative activities of Chlorphenamine.
ChlorphenoxamineMephentermine may decrease the sedative activities of Chlorphenoxamine.
ChlorphentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Chlorphentermine.
ChlorpromazineChlorpromazine may decrease the stimulatory activities of Mephentermine.
ChlorprothixeneChlorprothixene may decrease the stimulatory activities of Mephentermine.
CimetidineMephentermine may decrease the sedative activities of Cimetidine.
CinnarizineMephentermine may decrease the sedative activities of Cinnarizine.
ClemastineMephentermine may decrease the sedative activities of Clemastine.
ClenbuterolThe risk or severity of adverse effects can be increased when Mephentermine is combined with Clenbuterol.
ClomipramineClomipramine may increase the stimulatory activities of Mephentermine.
ClozapineClozapine may decrease the stimulatory activities of Mephentermine.
CodeineMephentermine may increase the analgesic activities of Codeine.
CyamemazineCyamemazine may decrease the stimulatory activities of Mephentermine.
CyclizineMephentermine may decrease the sedative activities of Cyclizine.
CyclobenzaprineCyclobenzaprine may increase the stimulatory activities of Mephentermine.
CyproheptadineMephentermine may decrease the sedative activities of Cyproheptadine.
DapiprazoleDapiprazole may decrease the stimulatory activities of Mephentermine.
DesipramineDesipramine may increase the stimulatory activities of Mephentermine.
DesloratadineMephentermine may decrease the sedative activities of Desloratadine.
DexbrompheniramineMephentermine may decrease the sedative activities of Dexbrompheniramine.
Dexchlorpheniramine maleateMephentermine may decrease the sedative activities of Dexchlorpheniramine maleate.
DextromoramideMephentermine may increase the analgesic activities of Dextromoramide.
DextropropoxypheneMephentermine may increase the analgesic activities of Dextropropoxyphene.
DezocineMephentermine may increase the analgesic activities of Dezocine.
DiclofenamideDiclofenamide may decrease the excretion rate of Mephentermine which could result in a lower serum level and potentially a reduction in efficacy.
DihydrocodeineMephentermine may increase the analgesic activities of Dihydrocodeine.
DihydroergotamineDihydroergotamine may increase the hypertensive activities of Mephentermine.
DihydroetorphineMephentermine may increase the analgesic activities of Dihydroetorphine.
DihydromorphineMephentermine may increase the analgesic activities of Dihydromorphine.
DimenhydrinateMephentermine may decrease the sedative activities of Dimenhydrinate.
DimetindeneMephentermine may decrease the sedative activities of Dimetindene.
DimetotiazineMephentermine may decrease the sedative activities of Dimetotiazine.
DiphenhydramineMephentermine may decrease the sedative activities of Diphenhydramine.
DiphenoxylateMephentermine may increase the analgesic activities of Diphenoxylate.
DobutamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Mephentermine.
DopamineThe risk or severity of adverse effects can be increased when Dopamine is combined with Mephentermine.
DosulepinDosulepin may increase the stimulatory activities of Mephentermine.
DoxazosinDoxazosin may decrease the vasoconstricting activities of Mephentermine.
DoxepinMephentermine may decrease the sedative activities of Doxepin.
DoxepinDoxepin may increase the stimulatory activities of Mephentermine.
DoxofyllineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Doxofylline.
DoxylamineMephentermine may decrease the sedative activities of Doxylamine.
DPDPEMephentermine may increase the analgesic activities of DPDPE.
DronabinolDronabinol may increase the tachycardic activities of Mephentermine.
DroperidolDroperidol may decrease the stimulatory activities of Mephentermine.
EmedastineMephentermine may decrease the sedative activities of Emedastine.
EphedrineThe risk or severity of adverse effects can be increased when Ephedrine is combined with Mephentermine.
EpinastineMephentermine may decrease the sedative activities of Epinastine.
EpinephrineThe risk or severity of adverse effects can be increased when Epinephrine is combined with Mephentermine.
ErgonovineErgonovine may increase the hypertensive activities of Mephentermine.
ErgotamineErgotamine may increase the hypertensive activities of Mephentermine.
EsmirtazapineMephentermine may decrease the sedative activities of Esmirtazapine.
EsmirtazapineEsmirtazapine may increase the stimulatory activities of Mephentermine.
EthopropazineMephentermine may decrease the sedative activities of Ethopropazine.
EthosuximideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Mephentermine.
EthoxzolamideEthoxzolamide may decrease the excretion rate of Mephentermine which could result in a lower serum level and potentially a reduction in efficacy.
EthylmorphineMephentermine may increase the analgesic activities of Ethylmorphine.
EtilefrineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Etilefrine.
EtorphineMephentermine may increase the analgesic activities of Etorphine.
FamotidineMephentermine may decrease the sedative activities of Famotidine.
FencamfamineFencamfamine may decrease the stimulatory activities of Mephentermine.
FenoterolThe risk or severity of adverse effects can be increased when Fenoterol is combined with Mephentermine.
FentanylThe serum concentration of Fentanyl can be decreased when it is combined with Mephentermine.
FexofenadineMephentermine may decrease the sedative activities of Fexofenadine.
FlunarizineMephentermine may decrease the sedative activities of Flunarizine.
FlupentixolFlupentixol may decrease the stimulatory activities of Mephentermine.
FluphenazineFluphenazine may decrease the stimulatory activities of Mephentermine.
FluspirileneFluspirilene may decrease the stimulatory activities of Mephentermine.
FurazolidoneFurazolidone may increase the hypertensive activities of Mephentermine.
GuanethidineThe serum concentration of Mephentermine can be decreased when it is combined with Guanethidine.
HaloperidolHaloperidol may decrease the stimulatory activities of Mephentermine.
HeroinMephentermine may increase the analgesic activities of Heroin.
HexamethylenetetramineThe serum concentration of Mephentermine can be decreased when it is combined with Hexamethylenetetramine.
HydracarbazineHydracarbazine may increase the hypertensive activities of Mephentermine.
HydrocodoneMephentermine may increase the analgesic activities of Hydrocodone.
HydromorphoneMephentermine may increase the analgesic activities of Hydromorphone.
Hydroxyamphetamine hydrobromideThe risk or severity of adverse effects can be increased when Mephentermine is combined with Hydroxyamphetamine hydrobromide.
HydroxyzineMephentermine may decrease the sedative activities of Hydroxyzine.
IloperidoneIloperidone may decrease the stimulatory activities of Mephentermine.
ImipramineImipramine may increase the stimulatory activities of Mephentermine.
IndoraminIndoramin may decrease the vasoconstricting activities of Mephentermine.
Ioflupane I-123Mephentermine may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
IproclozideIproclozide may increase the hypertensive activities of Mephentermine.
IproniazidIproniazid may increase the hypertensive activities of Mephentermine.
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Mephentermine.
IsoprenalineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Mephentermine.
IsothipendylMephentermine may decrease the sedative activities of Isothipendyl.
IsoxsuprineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Isoxsuprine.
KetobemidoneMephentermine may increase the analgesic activities of Ketobemidone.
KetotifenMephentermine may decrease the sedative activities of Ketotifen.
L-Glutamic AcidThe serum concentration of Mephentermine can be decreased when it is combined with L-Glutamic Acid.
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Mephentermine.
LevocabastineMephentermine may decrease the sedative activities of Levocabastine.
LevocetirizineMephentermine may decrease the sedative activities of Levocetirizine.
Levomethadyl AcetateMephentermine may increase the analgesic activities of Levomethadyl Acetate.
LevorphanolMephentermine may increase the analgesic activities of Levorphanol.
LinezolidLinezolid may increase the hypertensive activities of Mephentermine.
LithiumLithium may decrease the stimulatory activities of Mephentermine.
LodoxamideMephentermine may decrease the sedative activities of Lodoxamide.
LofentanilMephentermine may increase the analgesic activities of Lofentanil.
LoratadineMephentermine may decrease the sedative activities of Loratadine.
LoxapineLoxapine may decrease the stimulatory activities of Mephentermine.
LurasidoneLurasidone may decrease the stimulatory activities of Mephentermine.
MagaldrateMagaldrate may decrease the excretion rate of Mephentermine which could result in a lower serum level and potentially a reduction in efficacy.
Magnesium carbonateMagnesium carbonate may decrease the excretion rate of Mephentermine which could result in a lower serum level and potentially a reduction in efficacy.
Magnesium hydroxideMagnesium hydroxide may decrease the excretion rate of Mephentermine which could result in a lower serum level and potentially a reduction in efficacy.
Magnesium oxideMagnesium oxide may decrease the excretion rate of Mephentermine which could result in a lower serum level and potentially a reduction in efficacy.
Magnesium TrisilicateMagnesium Trisilicate may decrease the excretion rate of Mephentermine which could result in a lower serum level and potentially a reduction in efficacy.
MebanazineMebanazine may increase the hypertensive activities of Mephentermine.
MeclizineMephentermine may decrease the sedative activities of Meclizine.
MelperoneMelperone may decrease the stimulatory activities of Mephentermine.
MepyramineMephentermine may decrease the sedative activities of Mepyramine.
MequitazineMephentermine may decrease the sedative activities of Mequitazine.
MesoridazineMesoridazine may decrease the stimulatory activities of Mephentermine.
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Mephentermine.
MethadoneMephentermine may increase the analgesic activities of Methadone.
Methadyl AcetateMephentermine may increase the analgesic activities of Methadyl Acetate.
MethamphetamineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Methamphetamine.
MethapyrileneMephentermine may decrease the sedative activities of Methapyrilene.
MethazolamideMethazolamide may decrease the excretion rate of Mephentermine which could result in a lower serum level and potentially a reduction in efficacy.
MethotrimeprazineMethotrimeprazine may decrease the stimulatory activities of Mephentermine.
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Mephentermine.
Methylene blueMethylene blue may increase the hypertensive activities of Mephentermine.
MetiamideMephentermine may decrease the sedative activities of Metiamide.
MianserinMephentermine may decrease the sedative activities of Mianserin.
MidodrineThe risk or severity of adverse effects can be increased when Midodrine is combined with Mephentermine.
MinaprineMinaprine may increase the hypertensive activities of Mephentermine.
MirtazapineMephentermine may decrease the sedative activities of Mirtazapine.
MirtazapineMirtazapine may increase the stimulatory activities of Mephentermine.
MoclobemideMoclobemide may increase the hypertensive activities of Mephentermine.
MolindoneMolindone may decrease the stimulatory activities of Mephentermine.
MorphineMephentermine may increase the analgesic activities of Morphine.
NabiloneNabilone may increase the tachycardic activities of Mephentermine.
NalbuphineMephentermine may increase the analgesic activities of Nalbuphine.
NialamideNialamide may increase the hypertensive activities of Mephentermine.
NizatidineMephentermine may decrease the sedative activities of Nizatidine.
NorepinephrineThe risk or severity of adverse effects can be increased when Norepinephrine is combined with Mephentermine.
NormethadoneMephentermine may increase the analgesic activities of Normethadone.
NortriptylineNortriptyline may increase the stimulatory activities of Mephentermine.
NylidrinThe risk or severity of adverse effects can be increased when Mephentermine is combined with Nylidrin.
OctamoxinOctamoxin may increase the hypertensive activities of Mephentermine.
OlanzapineOlanzapine may decrease the stimulatory activities of Mephentermine.
OlopatadineMephentermine may decrease the sedative activities of Olopatadine.
OndansetronOndansetron may decrease the stimulatory activities of Mephentermine.
OpiumMephentermine may increase the analgesic activities of Opium.
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Mephentermine.
OsanetantOsanetant may decrease the stimulatory activities of Mephentermine.
OxycodoneMephentermine may increase the analgesic activities of Oxycodone.
OxymetazolineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Mephentermine.
OxymorphoneMephentermine may increase the analgesic activities of Oxymorphone.
PaliperidonePaliperidone may decrease the stimulatory activities of Mephentermine.
PargylinePargyline may increase the hypertensive activities of Mephentermine.
PemirolastMephentermine may decrease the sedative activities of Pemirolast.
PentazocineMephentermine may increase the analgesic activities of Pentazocine.
PerospironePerospirone may decrease the stimulatory activities of Mephentermine.
PerphenazinePerphenazine may decrease the stimulatory activities of Mephentermine.
PethidineMephentermine may increase the analgesic activities of Pethidine.
PhenelzinePhenelzine may increase the hypertensive activities of Mephentermine.
PhenindamineMephentermine may decrease the sedative activities of Phenindamine.
PheniprazinePheniprazine may increase the hypertensive activities of Mephentermine.
PheniramineMephentermine may decrease the sedative activities of Pheniramine.
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Mephentermine.
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Mephentermine.
PhenoxypropazinePhenoxypropazine may increase the hypertensive activities of Mephentermine.
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Mephentermine.
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Mephentermine.
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Mephentermine.
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Mephentermine.
PimozidePimozide may decrease the stimulatory activities of Mephentermine.
PipamperonePipamperone may decrease the stimulatory activities of Mephentermine.
PipotiazinePipotiazine may decrease the stimulatory activities of Mephentermine.
PirlindolePirlindole may increase the hypertensive activities of Mephentermine.
PivhydrazinePivhydrazine may increase the hypertensive activities of Mephentermine.
PrazosinPrazosin may decrease the vasoconstricting activities of Mephentermine.
ProcaterolThe risk or severity of adverse effects can be increased when Mephentermine is combined with Procaterol.
ProchlorperazineProchlorperazine may decrease the stimulatory activities of Mephentermine.
PromazinePromazine may decrease the stimulatory activities of Mephentermine.
PromethazineMephentermine may decrease the sedative activities of Promethazine.
PropericiazinePropericiazine may decrease the stimulatory activities of Mephentermine.
ProtriptylineProtriptyline may increase the stimulatory activities of Mephentermine.
PseudoephedrineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Pseudoephedrine.
QuetiapineQuetiapine may decrease the stimulatory activities of Mephentermine.
RacepinephrineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Racepinephrine.
RanitidineMephentermine may decrease the sedative activities of Ranitidine.
RasagilineRasagiline may increase the hypertensive activities of Mephentermine.
RemifentanilMephentermine may increase the analgesic activities of Remifentanil.
RemoxiprideRemoxipride may decrease the stimulatory activities of Mephentermine.
ReserpineReserpine may decrease the stimulatory activities of Mephentermine.
RisperidoneRisperidone may decrease the stimulatory activities of Mephentermine.
RitodrineThe risk or severity of adverse effects can be increased when Ritodrine is combined with Mephentermine.
Roxatidine acetateMephentermine may decrease the sedative activities of Roxatidine acetate.
SafrazineSafrazine may increase the hypertensive activities of Mephentermine.
SelegilineSelegiline may increase the hypertensive activities of Mephentermine.
SertindoleSertindole may decrease the stimulatory activities of Mephentermine.
SilodosinSilodosin may decrease the vasoconstricting activities of Mephentermine.
Spaglumic AcidMephentermine may decrease the sedative activities of Spaglumic Acid.
SufentanilMephentermine may increase the analgesic activities of Sufentanil.
SulpirideSulpiride may decrease the stimulatory activities of Mephentermine.
SynephrineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Synephrine.
TamsulosinTamsulosin may decrease the vasoconstricting activities of Mephentermine.
TapentadolMephentermine may increase the analgesic activities of Tapentadol.
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Mephentermine.
TerazosinTerazosin may decrease the vasoconstricting activities of Mephentermine.
TerbutalineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Mephentermine.
TerfenadineMephentermine may decrease the sedative activities of Terfenadine.
TesmilifeneMephentermine may decrease the sedative activities of Tesmilifene.
TetryzolineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Tetryzoline.
ThioproperazineThioproperazine may decrease the stimulatory activities of Mephentermine.
ThioridazineThioridazine may decrease the stimulatory activities of Mephentermine.
ThiothixeneThiothixene may decrease the stimulatory activities of Mephentermine.
ThonzylamineMephentermine may decrease the sedative activities of Thonzylamine.
TianeptineTianeptine may increase the stimulatory activities of Mephentermine.
ToloxatoneToloxatone may increase the hypertensive activities of Mephentermine.
TramadolMephentermine may increase the analgesic activities of Tramadol.
TranilastMephentermine may decrease the sedative activities of Tranilast.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Mephentermine.
TranylcypromineTranylcypromine may increase the hypertensive activities of Mephentermine.
TrifluoperazineTrifluoperazine may decrease the stimulatory activities of Mephentermine.
TriflupromazineTriflupromazine may decrease the stimulatory activities of Mephentermine.
TrimazosinTrimazosin may decrease the vasoconstricting activities of Mephentermine.
TrimipramineTrimipramine may increase the stimulatory activities of Mephentermine.
TripelennamineMephentermine may decrease the sedative activities of Tripelennamine.
TriprolidineMephentermine may decrease the sedative activities of Triprolidine.
TyramineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Tyramine.
Vitamin CThe serum concentration of Mephentermine can be decreased when it is combined with Vitamin C.
ZiprasidoneZiprasidone may decrease the stimulatory activities of Mephentermine.
ZotepineZotepine may decrease the stimulatory activities of Mephentermine.
ZuclopenthixolZuclopenthixol may decrease the stimulatory activities of Mephentermine.
Food InteractionsNot Available

Targets

Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Components:
NameUniProt IDDetails
Alpha-1A adrenergic receptorP35348 Details
Alpha-1B adrenergic receptorP35368 Details
Alpha-1D adrenergic receptorP25100 Details
Alpha-2A adrenergic receptorP08913 Details
Alpha-2B adrenergic receptorP18089 Details
Alpha-2C adrenergic receptorP18825 Details
References
  1. Ahlquist RP: Present state of alpha- and beta-adrenergic drugs I. The adrenergic receptor. Am Heart J. 1976 Nov;92(5):661-4. [PubMed:10722 ]
  2. Mohta M, Janani SS, Sethi AK, Agarwal D, Tyagi A: Comparison of phenylephrine hydrochloride and mephentermine sulphate for prevention of post spinal hypotension. Anaesthesia. 2010 Dec;65(12):1200-5. doi: 10.1111/j.1365-2044.2010.06559.x. [PubMed:21182601 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Components:
NameUniProt IDDetails
Beta-1 adrenergic receptorP08588 Details
Beta-2 adrenergic receptorP07550 Details
Beta-3 adrenergic receptorP13945 Details
References
  1. Mohta M, Janani SS, Sethi AK, Agarwal D, Tyagi A: Comparison of phenylephrine hydrochloride and mephentermine sulphate for prevention of post spinal hypotension. Anaesthesia. 2010 Dec;65(12):1200-5. doi: 10.1111/j.1365-2044.2010.06559.x. [PubMed:21182601 ]
Comments
comments powered by Disqus
Drug created on July 06, 2007 13:56 / Updated on August 17, 2016 12:23